Biotech Buyout Binge Continues
For the second week in a row, buyout rumors and merger speculation sent a number of biotech and specialty pharmaceutical shares higher.
For the second week in a row, buyout rumors and merger speculation sent a number of biotech and specialty pharmaceutical shares higher.
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Leave a Reply
Want to join the discussion?Feel free to contribute!